Compositions and methods of potentiating antimicrobials
Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.
1 . A method for treating or preventing a bacterial infection or bacterial biofilm comprising administering a therapeutically effective amount of a pharmaceutical composition comprising at least one anti-bacterial agent, at least one cannabinoid, and a pharmaceutically acceptable carrier,
wherein a weight ratio between the at least one anti-bacterial agent and the at least one cannabinoid is between about 250:1 and about 1:50,
wherein an anti-bacterial efficacy of the pharmaceutical composition is similar to, or better, than an anti-bacterial efficacy of a pharmaceutical composition comprising 2 to 150 times the amount of the at least one anti-bacterial agent without the at least one cannabinoid,
wherein the at least one anti-bacterial agent comprises an aminoglycoside, wherein the aminoglycoside is gentamicin or a salt thereof,
and
wherein the at least one cannabinoid comprises tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), or cannabigerol monomethyl ether (CBGM), a salt of any of the foregoing, or any combination thereof.
2 . The method of claim 1 , wherein the at least one anti-bacterial agent is administered intravenously, intramuscularly, topically, orally, or in a nebulized form.
3 . The method of claim 1 , wherein administering the pharmaceutical composition is associated with:
(a) an extension of susceptibility of the bacteria to at least one anti-bacterial agent compared to susceptibility of the bacteria to the at least one anti-bacterial agent without the at least one cannabinoid;
(b) a reduced side effect relative to the side effect resulting from administration of the at least one anti-bacterial agent without the at least one cannabinoid, wherein the side effect comprises hypersensitivity towards the at least one anti-bacterial agent, an allergic reaction to the at least one anti-bacterial agent, fever, nausea, diarrhea, or any combination thereof;
(c) an increase in anti-bacterial activity relative to the side effect resulting from administration of the at least one anti-bacterial agent without the at least one cannabinoid; and/or
(d) an extension of the therapeutic window relative to the side effect resulting from administration of the at least one anti-bacterial agent without the at least one cannabinoid.
4 . The method of claim 1 , wherein the bacterial infection or the bacterial biofilm comprises Staphylococcus spp. infection or biofilm, Pseudomonas aeruginosa infection or biofilm, Porphyromonas spp. infection or biofilm, Moraxella spp. infection or biofilm, Peptostreptococcus spp. infection or biofilm, Enterococcus spp. infection or biofilm, Escherichia coli infection or biofilm, Klebsiella infection or biofilm, Streptococcal infection or biofilm, Treponema pallidum subspecies pallidum infection or biofilm, and/or Borrelia infection or biofilm.
5 . A method for treating or preventing a bacterial infection or a bacterial biofilm in a subject in need thereof, comprising administering to the subject a combination of a first pharmaceutical composition comprising at least one anti-bacterial agent and a second pharmaceutical composition comprising at least one cannabinoid wherein a weight ratio between the at least one anti-bacterial agent and the at least one cannabinoid is between about 250:1 and about 1:50,
wherein the at least one anti-bacterial agent comprises an aminoglycoside, wherein the aminoglycoside is gentamicin or a salt thereof,
wherein the at least one cannabinoid comprises tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), or cannabigerol monomethyl ether (CBGM), a salt of any of the foregoing, or any combination thereof, and
wherein the combination has an anti-microbial efficacy similar to, or better than, the anti-microbial efficacy of the same first pharmaceutical composition comprising 2 to 150 times the amount of the anti-microbial agent without the second pharmaceutical composition comprising the at least one cannabinoid.
6 . The method of claim 5 , wherein the at least one anti-bacterial agent is administered intravenously, intramuscularly, topically, orally, or in a nebulized form.
7 . The method of claim 5 , wherein the at least one anti-bacterial agent is administered intravenously, intramuscularly, or orally.
8 . The method of claim 5 , wherein the at least one anti-bacterial agent is administered together or separately with the at least one cannabinoid.